Scleroderma.
After a review of some pathogenetic and pathologic aspects of scleroderma, the experimental effects of a group of agents that can inhibit the formation of connective tissue, especially the biosynthesis of collagen, are mentioned. These substances were transferred to clinical therapy of scleroderma. Regular determinations of disease activity and guidance of therapy with quantitative and semiquantitative physical and biochemical technics are of utmost importance because treatment without guidance allows for no disclosure of therapeutic failure or recurrence of the disease in due time for readjustment of the treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005973:Glutamine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000008:administration & dosage / Q000627:therapeutic use; D012594:Scleroderma, Localized / Q000188:drug therapy / Q000473:pathology; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
D005973:Glutamine; D010396:Penicillamine